-The Business Standard Data also show that several other leading domestic pharma companies have recalled their products from the US Frequent drug recalls, warning letters and import alerts from the US in the recent past have turned into a major concern for the Indian Pharmaceutical industry and investors. While Ranbaxy Laboratories recently pleaded guilty before the US authorities for its wrongdoings in the past, the crackdown on the drug companies seems to...
More »SEARCH RESULT
Total Matching Records found : 501
Why India Trails China-Amartya Sen
-The New York Times CAMBRIDGE, Mass. - MODERN India is, in many ways, a success. Its claim to be the world's largest democracy is not hollow. Its media is vibrant and free; Indians buy more newspapers every day than any other nation. Since independence in 1947, life expectancy at birth has more than doubled, to 66 years from 32, and per-capita income (adjusted for inflation) has grown fivefold. In recent decades,...
More »Bitter pill
-The Business Standard Drugs are unaffordable, but price control is the wrong answer There is little doubt that medicines in India are too expensive for most of the population. For the poorest 20 per cent of Indians, the expenditure on medicines alone is 85 per cent of what they spend on their health, according to the National Sample Survey. A World Bank study on the subject found that just out-of-pocket medical costs...
More »Who Manufactures Dirty Medicines?-Amit Sengupta
-Newsclick.in A few weeks back Fortune magazine and CNN carried a long online blog titled ‘Dirty Medicine' by Dinesh Thakur, a former employ of Ranbaxy, where he recounts how he came across several procedural and other lapses in the company's manufacturing facilities. Since then the Fortune blog has become one of the most widely circulated and commented upon business stories in the world. The story received attention as it came in the...
More »Prices of key drugs to be cut by up to half-Sushmi Dey
-The Business Standard NPPA to soon notify prices in line with new pharma pricing policy Some key cancer drugs, antibiotics and medicines to treat cardiovascular diseases and tuberculosis are set to become cheaper by up to 50 per cent within the next 45 days. The National Pharmaceutical Pricing Authority (NPPA) will soon notify prices of as many as 150 packs of essential medicines in line with the new pharma pricing policy, according...
More »
